283 related articles for article (PubMed ID: 19574233)
1. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis.
Little MA; Nightingale P; Verburgh CA; Hauser T; De Groot K; Savage C; Jayne D; Harper L;
Ann Rheum Dis; 2010 Jun; 69(6):1036-43. PubMed ID: 19574233
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy.
Lorenzen J; Lovric S; Krämer R; Haller H; Haubitz M
Ann Rheum Dis; 2010 Jun; 69(6):1169-71. PubMed ID: 20424002
[TBL] [Abstract][Full Text] [Related]
3. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.
Harper L; Savage CO
Rheumatology (Oxford); 2005 Apr; 44(4):495-501. PubMed ID: 15613403
[TBL] [Abstract][Full Text] [Related]
4. Opportunistic infections are preceded by a rapid fall in antineutrophil cytoplasmic antibody (ANCA) titer in patients with ANCA associated vasculitis.
Palsson R; Choi HK; Niles JL
J Rheumatol; 2002 Mar; 29(3):505-10. PubMed ID: 11908563
[TBL] [Abstract][Full Text] [Related]
5. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Keogh KA; Wylam ME; Stone JH; Specks U
Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Gao Y; Chen M; Ye H; Yu F; Guo XH; Zhao MH
Rheumatology (Oxford); 2008 Oct; 47(10):1515-20. PubMed ID: 18676500
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
[TBL] [Abstract][Full Text] [Related]
8. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies.
Brijker F; Magee CC; Tervaert JW; O'Neill S; Walshe JJ
Clin Nephrol; 1999 Dec; 52(6):344-51. PubMed ID: 10604641
[TBL] [Abstract][Full Text] [Related]
9. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
Heijl C; Harper L; Flossmann O; Stücker I; Scott DG; Watts RA; Höglund P; Westman K; Mahr A;
Ann Rheum Dis; 2011 Aug; 70(8):1415-21. PubMed ID: 21616914
[TBL] [Abstract][Full Text] [Related]
10. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients.
Kamali S; Erer B; Artim-Esen B; Gul A; Ocal L; Konice M; Aral O; Inanc M
J Rheumatol; 2010 Feb; 37(2):374-8. PubMed ID: 20008921
[TBL] [Abstract][Full Text] [Related]
11. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
[TBL] [Abstract][Full Text] [Related]
12. Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients.
Lai QY; Ma TT; Li ZY; Chang DY; Zhao MH; Chen M
J Rheumatol; 2014 Sep; 41(9):1849-55. PubMed ID: 25086076
[TBL] [Abstract][Full Text] [Related]
13. Outcome of thirty patients with ANCA-associated renal vasculitis admitted to the intensive care unit.
Frausova D; Brejnikova M; Hruskova Z; Rihova Z; Tesar V
Ren Fail; 2008; 30(9):890-5. PubMed ID: 18925529
[TBL] [Abstract][Full Text] [Related]
14. Serum leptin and ghrelin correlate with disease activity in ANCA-associated vasculitis.
Kümpers P; Horn R; Brabant G; Woywodt A; Schiffer M; Haller H; Haubitz M
Rheumatology (Oxford); 2008 Apr; 47(4):484-7. PubMed ID: 18281689
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors.
Stassen PM; Derks RP; Kallenberg CG; Stegeman CA
Rheumatology (Oxford); 2008 Apr; 47(4):530-4. PubMed ID: 18356178
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan.
Itabashi M; Takei T; Yabuki Y; Suzuki H; Ando M; Akamatsu M; Yamazaki M; Mitobe M; Watanabe Y; Mochizuki T; Nitta K
Nephron Clin Pract; 2010; 115(1):c21-7. PubMed ID: 20173346
[TBL] [Abstract][Full Text] [Related]
17. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effect and clinical findings in patients with MPO-ANCA associated vasculitis syndrome].
Yoshida A; Takeda A; Fukuda M; Toda S; Morozumi K
Ryumachi; 2000 Feb; 40(1):1-8. PubMed ID: 10783659
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological characteristics and outcomes of Chinese patients with primary anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with immune complex deposition in kidney.
Yu F; Chen M; Wang SX; Zou WZ; Zhao MH; Wang HY
Nephrology (Carlton); 2007 Feb; 12(1):74-80. PubMed ID: 17295665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
